<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02354833</url>
  </required_header>
  <id_info>
    <org_study_id>1406316590</org_study_id>
    <nct_id>NCT02354833</nct_id>
  </id_info>
  <brief_title>Phenylephrine vs. Norepinephrine Infusion After Spinal Anesthesia for Cesarean Delivery</brief_title>
  <official_title>Phenylephrine vs. Norepinephrine Infusion in Preventing Hypotension After Spinal Anesthesia for Cesarean Delivery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>West Virginia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>West Virginia University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine if a medication called phenylephrine, which helps to
      control blood pressure, is more effective as a continuous intravenous (IV) infusion compared
      to continuous IV norepinephrine in maintaining blood pressure during a spinal anesthetic for
      a cesarean delivery. Good blood pressure control has been shown to decrease nausea and
      vomiting during and after cesarean delivery under spinal anesthesia. For elective cesarean
      delivery, all participants will receive spinal anesthesia with a local anesthetic and
      morphine (provides long term pain control after cesarean delivery). This study plans to
      enroll 80 pregnant research subjects 18 years and above. Patients will be randomly assigned
      according to a computer generated system to be in one of two groups.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be a prospective, experimental, observational, randomized open label, active
      treatment controlled trial.

      After written and informed consent are obtained, the study participants are randomly assigned
      using a computer generated table to 1 of 2 treatment groups prior to cesarean delivery.

      Group A will consist of: A continuous phenylephrine infusion 0.1 mcg/kg/min to maintain
      systolic blood pressure (SBP) within 100-120% of baseline before the spinal.

      Group B will consist of: A continuous norepinephrine infusion 0.05 mcg/kg/min to maintain
      systolic blood pressure (SBP) within 100-120% of baseline before the spinal.

      Patients will be admitted to holding area. Baseline arterial blood pressure and heart rate
      will be measured in supine position, with left uterine displacement. Baseline blood pressure
      will be calculated by taking the mean of three consecutive SBP measurements taken 5 minutes
      apart. IV will be placed. Intravenous ondansetron 4 mg and up to 500 mL of Lactated Ringers
      solution administered prior to induction of spinal anesthesia.

      The primary endpoint is the number of provider interventions needed to maintain the SBP
      within 100-120% of baseline for both groups. The secondary endpoint is nausea measured with
      each provider intervention after induction of spinal anesthesia, and immediately following
      delivery with 11 point verbal rating scale (0 = no nausea, 10 = worst possible nausea).
      Patients will also be instructed to report episodes of nausea at any other time during the
      study. Emesis will be recorded whenever present during the surgical procedure.

      Hypertensive episodes (SBP greater than 120% of baseline) will be treated with cessation of
      infusion. Infusion will be restarted when SBP has decreased to below the upper limit of the
      target range (120% of baseline SBP). If the infusion must be stopped on three occasions, it
      will be discontinued permanently and the blood pressure maintained with phenylephrine boluses
      only.

      Bradycardia (HR less than 50 BPM) will be treated with glycopyrrolate 0.4mg IV or ephedrine 5
      mg - 10 mg IV bolus.

      Study participants will receive a standard spinal anesthetic consisting of 0.75% hyperbaric
      bupivacaine (1.6 mL) plus preservative free morphine (0.2 mg) and fentanyl (20 mcg) at L3-4
      or L4-5 interspace (the standard of care for spinal anesthesia at Ruby Memorial Hospital).
      Prior to surgical incision, the spinal sensory level will be tested to the bilateral T4
      dermatomal level which is necessary for cesarean section under spinal anesthesia. The
      patients will be positioned supine with a wedge placed under the right hip to avoid
      aortocaval compression. Both the patient and the clinical research assistant (who will
      collect data) will not be blinded as to the administered phenylephrine infusion or
      norepinephrine infusion. The study will end when care is transferred to the labor and
      delivery room nurse.

      Measured variables will include blood pressure (BP), the number and type of provider
      interventions for control of blood pressure (BP), heart rate (HR), cardiac output (CO) as
      measured by a noninvasive CO monitor, APGAR scores at 1 and 5 minutes, nausea and vomiting,
      and fetal cord blood analysis at delivery.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Rescue Boluses to Maintain SBP</measure>
    <time_frame>At time of surgery, up to 2 hours</time_frame>
    <description>Number of rescue boluses to maintain the SBP within 100-120% of baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Median Total Rescue Bolus Dose of Ephedrine (mg) to Maintain SBP</measure>
    <time_frame>At time of surgery, up to 2 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Median Total Rescue Bolus Dose of Phenylephrine (mcg) to Maintain SBP</measure>
    <time_frame>At time of surgery, up to 2 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Experiencing Both Nausea and Emesis</measure>
    <time_frame>At time of surgery, up to 2 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">85</enrollment>
  <condition>Effects of; Anesthesia, in Labor and Delivery</condition>
  <arm_group>
    <arm_group_label>Phenylephrine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A continuous phenylephrine infusion at 0.1 mcg/kg/min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Norepinephrine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A continuous norepinephrine infusion at 0.05 mcg/kg/min</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phenylephrine</intervention_name>
    <arm_group_label>Phenylephrine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norepinephrine</intervention_name>
    <arm_group_label>Norepinephrine</arm_group_label>
    <other_name>Levophed</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The American Society of Anesthesiologists (ASA) Physical Status classification 1 and 2

          -  Pregnant women with singleton pregnancy

          -  Gestational age greater than 36 weeks

          -  Cesarean delivery under spinal anesthesia

        Exclusion Criteria:

          -  Use of cardiac medication or medication for blood pressure control

          -  Cardiovascular disease

          -  Multiple gestation

          -  Gestation diabetes requiring insulin

          -  History of postoperative nausea and vomiting

          -  Refusal to be in study

          -  Gastric bypass surgery

          -  History of chronic opioid use (chronic pain syndrome)

          -  Emergent caesarean delivery for maternal and/or fetal distress

          -  Eclampsia

          -  Progressive neurologic disease

          -  Infection at insertion site

          -  Allergy to local anesthetics, narcotics or other study medications.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>West Virginia University Hospital</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Afolabi BB, Lesi FE. Regional versus general anaesthesia for caesarean section. Cochrane Database Syst Rev. 2012 Oct 17;10:CD004350. doi: 10.1002/14651858.CD004350.pub3. Review.</citation>
    <PMID>23076903</PMID>
  </reference>
  <reference>
    <citation>Djabatey EA, Barclay PM. Difficult and failed intubation in 3430 obstetric general anaesthetics. Anaesthesia. 2009 Nov;64(11):1168-71. doi: 10.1111/j.1365-2044.2009.06060.x.</citation>
    <PMID>19825049</PMID>
  </reference>
  <reference>
    <citation>Ohpasanon P, Chinachoti T, Sriswasdi P, Srichu S. Prospective study of hypotension after spinal anesthesia for cesarean section at Siriraj Hospital: incidence and risk factors, Part 2. J Med Assoc Thai. 2008 May;91(5):675-80.</citation>
    <PMID>18672631</PMID>
  </reference>
  <reference>
    <citation>Lin FQ, Qiu MT, Ding XX, Fu SK, Li Q. Ephedrine versus phenylephrine for the management of hypotension during spinal anesthesia for cesarean section: an updated meta-analysis. CNS Neurosci Ther. 2012 Jul;18(7):591-7. doi: 10.1111/j.1755-5949.2012.00345.x.</citation>
    <PMID>22759268</PMID>
  </reference>
  <reference>
    <citation>Lee A, Ngan Kee WD, Gin T. A quantitative, systematic review of randomized controlled trials of ephedrine versus phenylephrine for the management of hypotension during spinal anesthesia for cesarean delivery. Anesth Analg. 2002 Apr;94(4):920-6, table of contents.</citation>
    <PMID>11916798</PMID>
  </reference>
  <reference>
    <citation>Stewart A, Fernando R, McDonald S, Hignett R, Jones T, Columb M. The dose-dependent effects of phenylephrine for elective cesarean delivery under spinal anesthesia. Anesth Analg. 2010 Nov;111(5):1230-7. doi: 10.1213/ANE.0b013e3181f2eae1. Epub 2010 Sep 14.</citation>
    <PMID>20841418</PMID>
  </reference>
  <reference>
    <citation>Allen TK, George RB, White WD, Muir HA, Habib AS. A double-blind, placebo-controlled trial of four fixed rate infusion regimens of phenylephrine for hemodynamic support during spinal anesthesia for cesarean delivery. Anesth Analg. 2010 Nov;111(5):1221-9. doi: 10.1213/ANE.0b013e3181e1db21. Epub 2010 May 21. Erratum in: Anesth Analg. 2011 Oct;113(4):800.</citation>
    <PMID>20495139</PMID>
  </reference>
  <reference>
    <citation>Ngan Kee WD, Khaw KS, Ng FF. Comparison of phenylephrine infusion regimens for maintaining maternal blood pressure during spinal anaesthesia for Caesarean section. Br J Anaesth. 2004 Apr;92(4):469-74. Epub 2004 Feb 20.</citation>
    <PMID>14977792</PMID>
  </reference>
  <reference>
    <citation>Doherty A, Ohashi Y, Downey K, Carvalho JC. Phenylephrine infusion versus bolus regimens during cesarean delivery under spinal anesthesia: a double-blind randomized clinical trial to assess hemodynamic changes. Anesth Analg. 2012 Dec;115(6):1343-50. doi: 10.1213/ANE.0b013e31826ac3db. Epub 2012 Sep 25.</citation>
    <PMID>23011562</PMID>
  </reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 20, 2015</study_first_submitted>
  <study_first_submitted_qc>January 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2015</study_first_posted>
  <results_first_submitted>April 26, 2016</results_first_submitted>
  <results_first_submitted_qc>January 3, 2017</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 4, 2017</results_first_posted>
  <last_update_submitted>January 3, 2017</last_update_submitted>
  <last_update_submitted_qc>January 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>West Virginia University</investigator_affiliation>
    <investigator_full_name>Manuel C. Vallejo MD , DMD</investigator_full_name>
    <investigator_title>Chair; Professor</investigator_title>
  </responsible_party>
  <keyword>Hypotension</keyword>
  <keyword>Cesarean Delivery</keyword>
  <keyword>Phenylephrine</keyword>
  <keyword>Spinal Anesthesia</keyword>
  <keyword>Norepinephrine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Phenylephrine</mesh_term>
    <mesh_term>Oxymetazoline</mesh_term>
    <mesh_term>Norepinephrine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Phenylephrine</title>
          <description>A continuous phenylephrine infusion at 0.1 mcg/kg/min
Phenylephrine</description>
        </group>
        <group group_id="P2">
          <title>Norepinephrine</title>
          <description>A continuous norepinephrine infusion at 0.05 mcg/kg/min
Norepinephrine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>We conducted a prospective, observational, randomized, open labeled trial on parturient scheduled for elective cesarean delivery under spinal anesthesia.</population>
      <group_list>
        <group group_id="B1">
          <title>Phenylephrine</title>
          <description>A continuous phenylephrine infusion at 0.1 mcg/kg/min
Phenylephrine</description>
        </group>
        <group group_id="B2">
          <title>Norepinephrine</title>
          <description>A continuous norepinephrine infusion at 0.05 mcg/kg/min
Norepinephrine</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="38"/>
            <count group_id="B2" value="43"/>
            <count group_id="B3" value="81"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="81"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.1" spread="5.6"/>
                    <measurement group_id="B2" value="31.2" spread="6.8"/>
                    <measurement group_id="B3" value="30.15" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="81"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Rescue Boluses to Maintain SBP</title>
        <description>Number of rescue boluses to maintain the SBP within 100-120% of baseline</description>
        <time_frame>At time of surgery, up to 2 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phenylephrine</title>
            <description>A continuous phenylephrine infusion at 0.1 mcg/kg/min
Phenylephrine</description>
          </group>
          <group group_id="O2">
            <title>Norepinephrine</title>
            <description>A continuous norepinephrine infusion at 0.05 mcg/kg/min
Norepinephrine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Rescue Boluses to Maintain SBP</title>
          <description>Number of rescue boluses to maintain the SBP within 100-120% of baseline</description>
          <units>rescue boluses</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.12</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Experiencing Both Nausea and Emesis</title>
        <time_frame>At time of surgery, up to 2 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phenylephrine</title>
            <description>Cardiac Output as recorded by a non-invasive hemodynamic monitor</description>
          </group>
          <group group_id="O2">
            <title>Norepinephrine</title>
            <description>Cardiac Output as recorded by a non-invasive hemodynamic monitor</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Experiencing Both Nausea and Emesis</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percentage of participants with Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.2" lower_limit="47.9" upper_limit="78.5"/>
                    <measurement group_id="O2" value="51.2" lower_limit="36.3" upper_limit="66.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage of participants with Emesis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.3" lower_limit="12.3" upper_limit="40.3"/>
                    <measurement group_id="O2" value="16.3" lower_limit="5.3" upper_limit="27.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis is comparing the percentage of participants with Nausea</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.28</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis is comparing the percentage of participants with Emesis</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Median Total Rescue Bolus Dose of Ephedrine (mg) to Maintain SBP</title>
        <time_frame>At time of surgery, up to 2 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phenylephrine</title>
            <description>A continuous phenylephrine infusion at 0.1 mcg/kg/min
Phenylephrine</description>
          </group>
          <group group_id="O2">
            <title>Norepinephrine</title>
            <description>A continuous norepinephrine infusion at 0.05 mcg/kg/min
Norepinephrine</description>
          </group>
        </group_list>
        <measure>
          <title>Median Total Rescue Bolus Dose of Ephedrine (mg) to Maintain SBP</title>
          <units>mg</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="85"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.10</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Median Total Rescue Bolus Dose of Phenylephrine (mcg) to Maintain SBP</title>
        <time_frame>At time of surgery, up to 2 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phenylephrine</title>
            <description>A continuous phenylephrine infusion at 0.1 mcg/kg/min
Phenylephrine</description>
          </group>
          <group group_id="O2">
            <title>Norepinephrine</title>
            <description>A continuous norepinephrine infusion at 0.05 mcg/kg/min
Norepinephrine</description>
          </group>
        </group_list>
        <measure>
          <title>Median Total Rescue Bolus Dose of Phenylephrine (mcg) to Maintain SBP</title>
          <units>mcg</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50" lower_limit="0" upper_limit="1000"/>
                    <measurement group_id="O2" value="100" lower_limit="0" upper_limit="700"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.73</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Phenylephrine</title>
          <description>Hypotension requiring a rescue bolus</description>
        </group>
        <group group_id="E2">
          <title>Norepinephrine</title>
          <description>Hypotension requiring a rescue bolus</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="24" subjects_affected="24" subjects_at_risk="38"/>
                <counts group_id="E2" events="22" subjects_affected="22" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>38 subjects were enrolled in the phenylephrine group and none excluded. 47 subjects were enrolled in the norepinephrine group; 4 patients excluded (2 patients due to monitoring equipment failure, and 2 patients due to emergency cesarean deliveries).</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Manuel C. Vallejo, Chair of Department of Anesthesiology</name_or_title>
      <organization>West Virginia University</organization>
      <phone>304-598-4929</phone>
      <email>mvallejo@wvumediciane.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

